Can I Take Glycine with PT-141 (Bremelanotide)?

What Is PT-141 (Bremelanotide) and How Does It Work?

PT-141, sold under the brand name Vyleesi, is a synthetic cyclic heptapeptide that activates melanocortin receptors, primarily MC3R and MC4R, in the central nervous system. The FDA approved it in June 2019 for HSDD in premenopausal women at a subcutaneous dose of 1.75 mg administered 45 minutes before anticipated sexual activity [1]. Off-label, prescribers use it for male erectile dysfunction, though this indication lacks FDA approval.

Mechanism of Action

Bremelanotide does not act on sex hormone receptors or vascular tissue directly. Instead, it modulates dopaminergic and noradrenergic pathways in the hypothalamus and limbic system, increasing sexual motivation at the level of the brain [2]. This central mechanism distinguishes it from PDE5 inhibitors such as sildenafil, which act peripherally on vascular smooth muscle.

Pharmacokinetic Profile

After subcutaneous injection, bremelanotide reaches peak plasma concentration (Cmax) in roughly 1 hour. Its half-life is approximately 2.7 hours, and it is metabolized primarily by hydrolysis of the amide bonds, not by cytochrome P450 enzymes [1]. This is a key fact: because CYP enzymes are not involved, the drug has a low potential for classic pharmacokinetic drug-supplement interactions.

Renal clearance accounts for a significant portion of elimination. Patients with severe renal impairment (creatinine clearance <30 mL/min) show increased exposure and are advised against use [1].

What Is Glycine and Why Do People Take It?

Glycine is the smallest proteinogenic amino acid. Endogenously, it serves as a precursor for collagen, glutathione, creatine, and heme. As a supplement, typical doses range from 3 g to 10 g per day. People take glycine most often for three purposes: improved sleep quality, blood glucose support, and musculoskeletal or skin collagen synthesis.

Sleep and Neurological Effects

The sleep application is the best-studied. A randomized, double-blind, crossover trial published in Sleep and Biological Rhythms (N=11) found that 3 g of glycine taken before bed reduced subjective fatigue and improved sleep quality scores compared with placebo [3]. A separate study in Neuropsychopharmacology showed glycine lowered core body temperature and shortened time to slow-wave sleep onset in rats, a finding supported by human polysomnography data [4].

Glycine acts as an inhibitory neurotransmitter in the spinal cord and brainstem via strychnine-sensitive glycine receptors, and it also modulates NMDA receptor activity as a co-agonist [5]. These CNS properties are relevant when combining it with a drug like bremelanotide that also acts centrally.

Glycemic and Metabolic Effects

Glycine may improve insulin sensitivity. A study in Diabetes Care (N=60) found that glycine supplementation at 5 g/day for 3 months reduced HbA1c and fasting glucose in patients with type 2 diabetes compared with placebo [6]. Separate research published in The American Journal of Clinical Nutrition found elevated plasma glycine concentrations correlated inversely with insulin resistance in a population cohort [7]. For patients taking bremelanotide who also have metabolic conditions, this glucose-lowering tendency is a mild but real consideration.

Collagen and Connective Tissue

Glycine comprises roughly 33% of collagen's amino acid content by mass [8]. Supplementation at doses of 10 g/day in women has been shown to increase skin elasticity and reduce wrinkle depth in a double-blind, placebo-controlled trial published in Skin Pharmacology and Physiology [9]. This use has no direct interaction with bremelanotide.

Does Glycine Interact with PT-141 (Bremelanotide)?

The interaction is pharmacodynamic, not pharmacokinetic. No published trial has evaluated this combination directly. The inference is built from individual mechanistic profiles.

Pharmacokinetic Assessment: No Interaction Expected

Bremelanotide is metabolized by peptide hydrolysis, not CYP1A2, CYP2D6, CYP3A4, or other hepatic enzymes [1]. Glycine at supplemental doses does not meaningfully inhibit or induce these pathways either [10]. There is no shared transporter competition documented in the literature. The FDA label for bremelanotide lists no supplement interactions and specifically flags only the risk of slowing absorption of co-administered oral medications due to transient nausea-related gastric slowing [1].

Because glycine is typically taken orally and bremelanotide is injected subcutaneously, even the gastric-absorption concern is largely irrelevant.

Pharmacodynamic Overlap: Central Nervous System

Both compounds act in the CNS, albeit through different receptor systems. Bremelanotide stimulates MC3R/MC4R to increase sexual arousal signaling [2]. Glycine, at doses above 3 g before sleep, promotes inhibitory glycinergic and NMDA-modulating effects that reduce alertness and lower core body temperature [4].

If glycine is taken in the evening for sleep and bremelanotide is used earlier in the day, there is minimal functional overlap. If both are taken within the same 2-to-3-hour window, the sedating tendency of glycine could theoretically blunt the CNS arousal that bremelanotide is intended to produce. This has not been studied formally, but the mechanistic logic is straightforward.

Blood Pressure: A Monitoring Point

Bremelanotide transiently raises blood pressure. In the FDA approval trials (RECONNECT, N=1,247 women across two Phase 3 studies), mean systolic blood pressure rose by approximately 6 mmHg and diastolic by approximately 3 mmHg within 12 hours of dosing, returning to baseline by 12 hours post-injection [1]. Glycine has no clinically meaningful pressor or depressor effect at standard doses. Blood pressure monitoring remains advisable after each bremelanotide dose regardless of glycine use.

Glycemic Overlap

If a patient uses glycine for blood glucose support (5 g/day) and is also managing metabolic syndrome or prediabetes, the mild insulin-sensitizing effect of glycine [6] could interact with any metabolic shifts from bremelanotide. Bremelanotide itself has not been shown to significantly alter fasting glucose in clinical trials, so the net glycemic interaction risk is low. Diabetic patients should simply continue routine glucose monitoring.

Timing and Dosing Recommendations

The absence of a mandatory separation window gives flexibility. The following approach reflects the mechanistic evidence available.

Suggested Timing Framework

For patients who use glycine at night (3 g to 5 g taken 30 to 60 minutes before bed for sleep) and bremelanotide on an as-needed basis (1.75 mg SC, 45 minutes before sexual activity):

• No separation required if use times differ by 4 or more hours. Bremelanotide's half-life of 2.7 hours means plasma levels are negligible within 10 to 12 hours.
• Avoid concurrent dosing within 2 hours if either sedation risk or maximal arousal response is a clinical priority.
• Collagen-dose glycine (10 g taken with morning meals) has zero overlap concern with an evening or afternoon bremelanotide dose.

Dose Ranges in Context

Glycine supplement doses studied in clinical trials range from 3 g/day (sleep) [3] to 10 g/day (skin collagen) [9] to 15 g/day (metabolic studies) [7]. None of these doses have been evaluated alongside bremelanotide. At doses above 10 g, some individuals report mild gastrointestinal discomfort, which could compound the nausea that affects up to 40% of bremelanotide users in Phase 3 trials [1].

Keeping glycine at or below 5 g/day and timing it separately from bremelanotide minimizes any additive GI burden.

Safety Evidence and What Guidelines Say

FDA Label Guidance

The Vyleesi prescribing information explicitly states that bremelanotide may slow the rate of absorption of orally administered drugs due to nausea and vomiting [1]. This is the only drug-interaction mechanism flagged for the drug class. Glycine, taken as a supplement outside the peri-dose window, is not subject to this concern.

The label also notes bremelanotide is contraindicated in patients with cardiovascular disease, in part because of the transient blood pressure increase [1]. Glycine does not add cardiovascular risk.

Glycine Safety Profile

The U.S. National Library of Medicine classifies glycine as "possibly safe" when used orally in appropriate doses [10]. Long-term supplementation up to 15 g/day has been studied without serious adverse events in adult populations [7]. The amino acid is GRAS-listed (generally recognized as safe) by the FDA [10].

No Interaction Flag in Current Databases

As of the most recent review of Natural Medicines and the FDA drug interaction databases, no formal interaction between glycine and bremelanotide is listed [1, 10]. This absence of a flag does not guarantee safety, but it is consistent with the mechanistic analysis above.

Who Should Be More Cautious?

Most healthy adults who take glycine for sleep or collagen support face minimal added risk when also prescribed bremelanotide. Some groups warrant additional attention.

Patients with Cardiovascular Disease

Bremelanotide is not recommended in patients with cardiovascular disease because of its pressor effect [1]. Glycine is not a concern in this context, but the population itself requires closer monitoring of blood pressure after each bremelanotide dose regardless of other supplements.

Patients with Type 2 Diabetes or Prediabetes

Glycine at 5 g/day may lower fasting glucose and HbA1c over weeks [6]. Patients on insulin or sulfonylureas who add glycine should monitor glucose more frequently during the first 4 to 8 weeks of supplementation. Bremelanotide does not compound this risk, but the glycine-glucose interaction alone justifies the monitoring step.

Patients Prone to Nausea

Nausea is the most common adverse event with bremelanotide, reported in up to 40% of users in Phase 3 trials [1]. High-dose glycine (above 10 g) can independently cause nausea and loose stools [10]. Taking both on the same day increases GI symptom burden in susceptible individuals. Splitting glycine across smaller doses (2.5 g twice daily rather than 5 g once) reduces this overlap.

Patients with Renal Impairment

Bremelanotide exposure increases in patients with creatinine clearance <30 mL/min [1]. Glycine is renally cleared as well, and high-dose amino acid supplementation in chronic kidney disease requires nephrologist input. This population should avoid combining either compound without specialist guidance.

Practical Steps If You Are Already Taking Both

Many patients start glycine for sleep before a bremelanotide prescription is added. The following steps apply.

First, confirm your glycine dose and timing with your prescribing clinician. A simple shift to evening glycine (if you currently take it in the morning) creates clear separation from daytime or afternoon bremelanotide use.

Second, track blood pressure after the first three to five bremelanotide doses. The FDA-observed mean rise of 6 mmHg systolic [1] is transient, but knowing your individual response matters.

Third, if you have metabolic syndrome or prediabetes, check fasting glucose every two weeks for the first month of concurrent use. The glucose-lowering effect of glycine [6] is generally beneficial but needs to be accounted for if you adjust diabetes medications during this period.

Fourth, report any new or worsening nausea to your prescriber. A dose reduction in glycine from 5 g to 3 g per day or shifting to morning collagen-support dosing may resolve it without discontinuing either compound.

What Clinicians Should Document

When prescribing bremelanotide to a patient already taking glycine, the clinical note should include the following elements: current glycine dose and timing, baseline blood pressure, baseline fasting glucose if the patient has any metabolic condition, and a plan for a 4-to-6-week follow-up to reassess.

The Endocrine Society's 2023 clinical practice guidelines on female sexual dysfunction note that patient-reported supplement use should be systematically reviewed before initiating pharmacological treatment for HSDD, because patient expectations and concurrent supplement effects can confound treatment response assessment [11].

Evidence Gaps and Future Research

No randomized controlled trial has examined glycine and bremelanotide together. The mechanistic inference developed here is supported by each compound's individual data, but the absence of direct evidence is a genuine limitation.

Future research could address three questions. Does concurrent glycine use (3 g before sleep) reduce subjective sexual desire scores measured on the Female Sexual Function Index the following morning after bremelanotide use the prior evening? Does glycine's NMDA-modulatory activity alter the MC4R signaling that drives bremelanotide's arousal effect at the neural circuit level? And does the mild insulin-sensitizing effect of chronic glycine supplementation modify the metabolic milieu in which bremelanotide is used, potentially affecting its CNS pharmacodynamics?

Until this data exists, clinical guidance rests on mechanistic plausibility and the absence of a documented harm signal.